Patents by Inventor Shawn P. Iadonato

Shawn P. Iadonato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190002477
    Abstract: Disclosed herein are compounds, pharmaceutical compositions, and related methods for the treatment of viral infection, including RNA viral infection in subjects. The compounds, pharmaceutical compositions, and methods can modulate the innate immune antiviral response in vertebrate cells, including activating the RIG-I pathway.
    Type: Application
    Filed: January 31, 2018
    Publication date: January 3, 2019
    Applicant: Kineta, Inc.
    Inventors: Shawn P. Iadonato, Kristin M. Bedard, Kerry W. Fowler, Ikenna Madu, Shari Kaiser
  • Publication number: 20180264080
    Abstract: Disclosed herein are methods for the topical treatment of inflammation of the skin and mucosa by applying a pharmaceutical composition including a protein or peptide that blocks the Kv1.3 potassium channel. The proteins and peptides can include an ShK-based protein and peptide.
    Type: Application
    Filed: January 7, 2016
    Publication date: September 20, 2018
    Applicant: KINETA ONE, LLC
    Inventors: Shawn P. Iadonato, Eric Tarcha, Kurt Lustig
  • Patent number: 9956285
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: May 1, 2018
    Assignee: Kineta, Inc.
    Inventors: Shawn P. Iadonato, Kristin M. Bedard, Myra Wang Imanaka, Kerry W. Fowler
  • Patent number: 9937230
    Abstract: Disclosed herein are methods of treating ophthalmic conditions such as dry eye and uveitis by administering a pharmaceutical composition including a toxin-based therapeutic peptide. The peptide can include an acid or amide at the C-terminus and can be attached to an organic or inorganic chemical entity that has an anionic charge.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: April 10, 2018
    Assignee: Kineta One, LLC
    Inventors: Shawn P. Iadonato, Ernesto J. Munoz
  • Patent number: 9884876
    Abstract: Disclosed herein are compounds, pharmaceutical compositions, and related methods for the treatment of viral infection, including RNA viral infection in subjects. The compounds, pharmaceutical compositions, and methods can modulate the innate immune antiviral response in vertebrate cells, including activating the RIG-I pathway.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: February 6, 2018
    Assignee: Kineta, Inc.
    Inventors: Shawn P. Iadonato, Kristin M. Bedard, Kerry W. Fowler, Ikenna Madu, Shari Kaiser
  • Patent number: 9878058
    Abstract: Disclosed herein are pharmaceutical compositions having the sequence Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys-His-Ser-Xaa-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys (SEQ ID NO:1). The disclosed compositions can include an acid or amide at the C-terminus of SEQ ID NO: 1 and the polypeptide can be attached to an organic or inorganic chemical entity that has an anionic charge. The polypeptide can be detectably labeled for diagnostic purposes. Methods of manufacturing and using the pharmaceutical compounds are also disclosed.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: January 30, 2018
    Assignee: Kv1.3 Therapeutics, Inc.
    Inventors: Shawn P. Iadonato, Eric J. Tarcha
  • Publication number: 20170258897
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Application
    Filed: January 30, 2017
    Publication date: September 14, 2017
    Applicant: Kineta, Inc.
    Inventors: Shawn P. Iadonato, Kristin M. Bedard, Myra Wang Imanaka, Kerry W. Fowler
  • Publication number: 20170057978
    Abstract: Disclosed herein are compounds, pharmaceutical compositions, and related methods for the treatment of viral infection, including RNA viral infection in subjects. The compounds, pharmaceutical compositions, and methods can modulate the innate immune antiviral response in vertebrate cells, including activating the RIG-I pathway.
    Type: Application
    Filed: May 8, 2015
    Publication date: March 2, 2017
    Applicant: Kineta, Inc.
    Inventors: Shawn P. Iadonato, Kristin M. Bedard, Kerry W. Fowler, Ikenna Madu, Shari Kaiser
  • Patent number: 9555106
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: January 31, 2017
    Assignee: Kineta, Inc.
    Inventors: Shawn P. Iadonato, Kristin Bedard, Myra Wang Imanaka, Kerry W. Fowler
  • Publication number: 20160338967
    Abstract: Depot formulations including therapeutic proteins are provided. The therapeutic proteins can be toxin-based therapeutic proteins. The depot formulations release the therapeutic protein within sustained effective levels for at least one month following a single administration. The toxin-based therapeutic proteins can include ShK-based proteins.
    Type: Application
    Filed: December 23, 2014
    Publication date: November 24, 2016
    Applicant: KINETA ONE, LLC
    Inventors: Shawn P. IADONATO, Ernesto J. MUNOZ, James CHESKO, Eric J. TARCHA
  • Publication number: 20160331847
    Abstract: Disclosed herein are pharmaceutical compositions having the sequence Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys-His-Ser-Xaa-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys (SEQ ID NO:1). The disclosed compositions can include an acid or amide at the C-terminus of SEQ ID NO:1 and the polypeptide can be attached to an organic or inorganic chemical entity that has an anionic charge. The polypeptide can be detectably labeled for diagnostic purposes. Methods of manufacturing and using the pharmaceutical compounds are also disclosed.
    Type: Application
    Filed: July 1, 2016
    Publication date: November 17, 2016
    Applicant: Kineta One, LLC
    Inventors: Shawn P. Iadonato, Eric J. Tarcha
  • Patent number: 9458492
    Abstract: Disclosed herein are methods for identifying compounds for the treatment of viral infection, including RNA viral infection and uses of the compounds as pharmaceutical compositions. The identified compounds modulate the RIG-I pathway in vertebrate cells.
    Type: Grant
    Filed: February 23, 2012
    Date of Patent: October 4, 2016
    Assignee: Kineta, Inc.
    Inventors: Shawn P Iadonato, Kristin Bedard
  • Patent number: 9408826
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: August 9, 2016
    Assignee: Kineta, Inc.
    Inventors: Shawn P. Iadonato, Kristin Bedard
  • Patent number: 9381261
    Abstract: Disclosed herein are pharmaceutical compositions having the sequence Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys-His-Ser-Xaa-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys (SEQ ID NO: 1). The disclosed compositions can include an acid or amide at the C-terminus of SEQ ID NO: 1 and the polypeptide can be attached to an organic or inorganic chemical entity that has an anionic charge. The polypeptide can be detectably labeled for diagnostic purposes. Methods of manufacturing and using the pharmaceutical compounds are also disclosed.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: July 5, 2016
    Assignee: Kineta One, LLC
    Inventors: Shawn P Iadonato, Eric J Tarcha
  • Publication number: 20160151457
    Abstract: Disclosed herein are methods of treating ophthalmic conditions such as dry eye and uveitis by administering a pharmaceutical composition including a toxin-based therapeutic peptide. The peptide can include an acid or amide at the C-terminus and can be attached to an organic or inorganic chemical entity that has an anionic charge.
    Type: Application
    Filed: July 22, 2014
    Publication date: June 2, 2016
    Applicant: Kineta One, LLC
    Inventors: Shawn P. Iadonato, Emesto J. Munoz
  • Publication number: 20160122312
    Abstract: Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of viral infection, including RNA viral infection, as well as compounds, pharmaceutical compositions, and methods for modulating the RIG-I pathway in a subject and/or in cells. These compounds are isoflavone derivatives, typically substituted at the 3-position with an aryl group and at the 7-position with a heterofunctional group.
    Type: Application
    Filed: July 16, 2014
    Publication date: May 5, 2016
    Inventors: Shawn P. Iadonato, Kristin M. Bedard, Kerry W. Fowler
  • Publication number: 20160102099
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Application
    Filed: December 2, 2015
    Publication date: April 14, 2016
    Inventors: Shawn P. Iadonato, Kristin M. Bedard, Myra Wang Imanaka, Kerry W. Fowler
  • Patent number: 9301952
    Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: April 5, 2016
    Assignee: Kineta, Inc.
    Inventors: Shawn P. Iadonato, Kristin Bedard
  • Publication number: 20160045627
    Abstract: Disclosed herein are pharmaceutical compositions having the sequence Arg-Ser-Cys-Ile-Asp-Thr-Ile-Pro-Lys-Ser-Arg-Cys-Thr-Ala-Phe-Gln-Cys-Lys-His-Ser-Xaa-Lys-Tyr-Arg-Leu-Ser-Phe-Cys-Arg-Lys-Thr-Cys-Gly-Thr-Cys (SEQ ID NO:1). The disclosed compositions can include an acid or amide at the C-terminus of SEQ ID NO: 1 and the polypeptide can be attached to an organic or inorganic chemical entity that has an anionic charge. The polypeptide can be detectably labeled for diagnostic purposes. Methods of manufacturing and using the pharmaceutical compounds are also disclosed.
    Type: Application
    Filed: August 26, 2015
    Publication date: February 18, 2016
    Inventors: Shawn P. Iadonato, Eric J. Tarcha
  • Publication number: 20160000869
    Abstract: Disclosed herein are methods of treating immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) comprising administering a toxin-based therapeutic peptide, such as an ShK-based peptide. The peptide can include an acid or amide at the C-terminus and/or the peptide can be attached to an organic or inorganic chemical entity that has an anionic charge.
    Type: Application
    Filed: March 5, 2014
    Publication date: January 7, 2016
    Inventors: Shawn P. Iadonato, Ernesto J. Munoz